资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B11529

Science. 2022-04;

Tongqing Zhou, Lingshu Wang, John Misasi, Amarendra Pegu, Yi Zhang, Darcy R Harris, Adam S Olia, Chloe Adrienna Talana, Eun Sung Yang, Man Chen, Misook Choe, Wei Shi, I-Ting Teng, Adrian Creanga, Claudia Jenkins, Kwanyee Leung, Tracy Liu, Erik-Stephane D Stancofski, Tyler Stephens, Baoshan Zhang, Yaroslav Tsybovsky, Barney S Graham, John R Mascola, Nancy J Sullivan, Peter D Kwong

Products/Services Used	Details	Operation
Custom Vector Construction	… kappa chain expression vectors, as appropriate (Genscript). ADG2 was kindly provided by … used for synthesis and cloning into corresponding pVRC8400 vectors (Genscript) (56, 57). For …	Get A Quote

摘要

The rapid spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (Omicron) variant and its resistance to neutralization by vaccinee and convalescent sera are driving a search for monoclonal antibodies with potent neutralization. To provide insight into effective neutralization, we determined cryo-electron microscopy structures and evaluated receptor binding domain (RBD) antibodies for their ability to bind and neutralize B.1.1.529. Mutations altered 16% of the B.1.1.529 RBD surface, clustered on an RBD ridge overlapping the angiotensin-converting enzyme 2 (ACE2)-binding surface and reduced binding of most antibodies. Substantial inhibitory activity was retained by select monoclonal... More